home / stock / gmtx / gmtx quote
Last: | $1.35 |
---|---|
Change Percent: | -0.74% |
Open: | $1.36 |
Close: | $1.35 |
High: | $1.41 |
Low: | $1.35 |
Volume: | 62,860 |
Last Trade Date Time: | 12/29/2022 03:39:20 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.35 | $1.36 | $1.35 | $1.41 | $1.35 | 62,860 | 12-29-2022 |
$1.35 | $1.23 | $1.35 | $1.36 | $1.18 | 116,537 | 12-28-2022 |
$1.35 | $1.7 | $1.35 | $1.71 | $1.33 | 2,681,173 | 12-27-2022 |
$1.55 | $1.53 | $1.55 | $1.61 | $1.53 | 60,710 | 12-26-2022 |
$1.55 | $1.53 | $1.55 | $1.61 | $1.53 | 60,710 | 12-23-2022 |
$1.55 | $1.55 | $1.55 | $1.63 | $1.55 | 100,102 | 12-22-2022 |
$1.54 | $1.5539 | $1.54 | $1.6301 | $1.52 | 55,479 | 12-21-2022 |
$1.6 | $1.61 | $1.6 | $1.69 | $1.57 | 92,079 | 12-20-2022 |
$1.6 | $1.53 | $1.6 | $1.61 | $1.47 | 43,680 | 12-19-2022 |
$1.555 | $1.52 | $1.555 | $1.57 | $1.5103 | 25,350 | 12-16-2022 |
$1.545 | $1.67 | $1.545 | $1.7 | $1.52 | 51,834 | 12-15-2022 |
$1.65 | $1.66 | $1.65 | $1.7 | $1.63 | 9,579 | 12-14-2022 |
$1.65 | $1.69 | $1.65 | $1.7 | $1.62 | 24,368 | 12-13-2022 |
$1.65 | $1.65 | $1.65 | $1.68 | $1.64 | 6,446 | 12-12-2022 |
$1.65 | $1.66 | $1.65 | $1.7 | $1.62 | 12,767 | 12-09-2022 |
$1.65 | $1.56 | $1.65 | $1.69 | $1.56 | 26,473 | 12-08-2022 |
$1.65 | $1.65 | $1.65 | $1.66 | $1.64 | 2,728 | 12-07-2022 |
$1.62 | $1.675 | $1.62 | $1.7 | $1.61 | 35,926 | 12-06-2022 |
$1.7 | $1.66 | $1.7 | $1.73 | $1.66 | 25,808 | 12-05-2022 |
$1.72 | $1.6 | $1.72 | $1.73 | $1.6 | 37,034 | 12-02-2022 |
News, Short Squeeze, Breakout and More Instantly...
Gemini Therapeutics Inc. Company Name:
GMTX Stock Symbol:
NASDAQ Market:
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria PR Newswire WATERTOWN, Mass. , Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on t...
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) PR Newswire AURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults with EPP in the United States ...